Journal
CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 62, Issue 15, Pages 1671-1681Publisher
SPRINGER BASEL AG
DOI: 10.1007/s00018-005-5082-7
Keywords
pyridoxamine; AGE; reactive oxygen species; reactive carbonyl compounds; diabetes; kidney stones; atherosclerosis; ageing
Categories
Funding
- NIDDK NIH HHS [DK-66415, DK-65138, DK-60251] Funding Source: Medline
Ask authors/readers for more resources
The discovery that pyridoxamine (PM) can inhibit glycation reactions and the formation of advanced glycation end products (AGEs) stimulated new interest in this B-6 vitamer as a prospective pharmacological agent for treatment of complications of diabetes. The mechanism of action of PM includes: (i) inhibition of AGE formation by blocking oxidative degradation of the Amadori intermediate of the Maillard reaction; (ii) scavenging of toxic carbonyl products of glucose and lipid degradation; and (iii) trapping of reactive oxygen species. The combination of these multiple activities along with PM safety posture it as a promising drug candidate for treatment of diabetic complications as well as other multifactorial chronic conditions in which oxidative reactions and carbonyl compounds confer pathogenicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available